Tisdag 26 November | 05:46:26 Europe / Stockholm
Svenska | English

Neodynamics

Bifogade filer

Kursutveckling under dagen för detta pressmeddelande (SEK).

Likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Tid*
2025-02-17 09:00 Bokslutskommuniké 2024
2024-11-19 - Kvartalsrapport 2024-Q3
2024-08-20 - Kvartalsrapport 2024-Q2
2024-07-31 - 15-6 2024
2024-05-23 - X-dag ordinarie utdelning NEOD 0.00 SEK
2024-05-22 - Årsstämma
2024-05-07 - Kvartalsrapport 2024-Q1
2024-02-16 - Bokslutskommuniké 2023
2024-02-16 - Split NEOD 100:1
2024-02-02 - Extra Bolagsstämma 2024
2023-11-27 - Kvartalsrapport 2023-Q3
2023-08-19 - Kvartalsrapport 2023-Q2
2023-07-27 - Extra Bolagsstämma 2023
2023-05-24 - X-dag ordinarie utdelning NEOD 0.00 SEK
2023-05-23 - Årsstämma
2023-05-11 - Kvartalsrapport 2023-Q1
2023-02-17 - Bokslutskommuniké 2022
2022-11-17 - Kvartalsrapport 2022-Q3
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-20 - X-dag ordinarie utdelning NEOD 0.00 SEK
2022-05-19 - Årsstämma
2022-05-12 - Kvartalsrapport 2022-Q1
2022-02-25 - Extra Bolagsstämma 2022
2022-02-16 - Bokslutskommuniké 2021
2021-11-17 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-27 - X-dag ordinarie utdelning NEOD 0.00 SEK
2021-05-26 - Årsstämma
2021-05-26 - Kvartalsrapport 2021-Q1
2021-02-17 - Bokslutskommuniké 2020
2020-11-19 - Extra Bolagsstämma 2020
2020-11-19 - Kvartalsrapport 2020-Q3
2020-08-21 - Kvartalsrapport 2020-Q2
2020-05-29 - X-dag ordinarie utdelning NEOD 0.00 SEK
2020-05-28 - Årsstämma
2020-05-26 - Kvartalsrapport 2020-Q1
2020-02-05 - Bokslutskommuniké 2019
2020-01-28 - Extra Bolagsstämma 2019
2019-11-21 - Kvartalsrapport 2019-Q3
2019-08-28 - Kvartalsrapport 2019-Q2
2019-05-24 - X-dag ordinarie utdelning NEOD 0.00 SEK
2019-05-23 - Årsstämma
2019-05-21 - Kvartalsrapport 2019-Q1
2019-02-21 - Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Neodynamics är verksamt inom medicinteknik. Idag är verksamheten inriktad mot att utveckla och kommersialisera produkter för behandling av kritiska sjukdomar. Via egenutvecklad mikropulsteknologi erbjuder bolaget precisionsbehandlingar mot bland annat cancer. Lösningarna används främst vid behandling avb bröstcancer hos kvinnor. Huvudkontoret ligger i Lidingö.
Update on NeoDynamics’ financial situation
2023-12-05 21:32:00

The Board and Management of NeoDynamics have secured short-term financing

As announced on 28 November, The Board and Management have been working to secure short-term financing by means of a loan. A loan of SEK 10 million has now been secured at market rates.

The Board and Management are pursuing a long-term solution that will secure sufficient capital to continue the commercialisation of NeoNavia® in Europe and the US, and expect to be able to publish a solution in the near future.

For further information, please contact:
Anna Eriksrud, CEO NeoDynamics AB, phone +46708 444 966 or e-mail anna.eriksrud@neodynamics.com
Aaron Wong, CFO NeoDynamics AB, phone +46790 101 714 or e-mail aaron.wong@neodynamics.com

About NeoDynamics
NeoDynamics AB is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound-guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in Europe and launches in USA during 2023. NeoDynamic’s shares are listed on Nasdaq First North Growth Market Stockholm (ticker: NEOD). The company’s Certified Adviser is Redeye AB.

About NeoNavia
NeoNavia is a modern biopsy system with a completely new patented pulse technology intended for ultrasound-guided tissue sampling. Each needle type is driven by the pulse technology providing a more controlled needle insertion and precise placement of the needle in the tumor whilst enabling high-quality tissue samples from both breasts and lymph nodes. The pulse biopsy system NeoNavia is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.

About Karolinska Institute
The Karolinska Institute is consistently ranked amongst the world's best medical schools, ranking 6th worldwide for medicine in 2021. The Nobel Assembly at the Karolinska Institute awards the Nobel Prize in Physiology or Medicine.

Attachments
Update on NeoDynamics’ financial situation

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden